About Venus MedTech
Venus MedTech is a company based in Hangzhou (China) founded in 2009 by Eric Zi. Venus MedTech has raised $37 million across 5 funding rounds from investors including Qiming Venture Partners, DCP and Goldman Sachs Investment Partners. The company has 691 employees as of December 31, 2024. Venus MedTech has completed 5 acquisitions, including InterValve, Keystone Heart and Transcatheter Technologies. Venus MedTech operates in a competitive market with competitors including Shockwave Medical, Cardiac Dimensions, Pi-Cardia, Symetis and Peijia Medical Technologies, among others.
- Headquarter Hangzhou, China
- Employees 691 as on 31 Dec, 2024
- Founders Eric Zi
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Venus Medtech (Hangzhou), Inc. Class H
-
Annual Revenue
$65.73 M (USD)-5.98as on Dec 31, 2024
-
Net Profit
-$99.72 M (USD)0.41as on Dec 31, 2024
-
EBITDA
-$38.37 M (USD)41.75as on Dec 31, 2024
-
Total Equity Funding
$37 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
Qiming Venture Partners
& 3 more
-
Employee Count
691
as on Dec 31, 2024
-
Investments & Acquisitions
InterValve
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Venus MedTech
Venus MedTech is a publicly listed company on the HKEX with ticker symbol 2500 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Venus MedTech
Venus MedTech has successfully raised a total of $37M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Venus MedTech
Venus MedTech has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiming Venture Partners, DCP and Goldman Sachs Investment Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed across multiple sectors by DCP.
|
Locked | Locked | Locked | |
|
DNV Capital is engaged in asset management for healthcare and technology industries.
|
Locked | Locked | Locked | |
|
Venture capital investments are directed toward multiple sectors.
|
Locked | Locked | Locked |
Investor details for Venus MedTech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Venus MedTech
Venus MedTech has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include InterValve, Keystone Heart and Transcatheter Technologies.
Investment portfolio details for Venus MedTech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of a novel transcatheter valve replacement system for mitral and tricuspid valve replacement. This system is designed for transfemoral delivery, avoiding open-heart surgery. Key features include a short profile to minimize ventricular protrusion and reduce LVOT obstruction risk, a robust anchoring mechanism, and an enhanced sealing solution to prevent paravalvular leaks. The device is currently limited to investigational use.
|
Locked | Locked | 2011 | Locked | |
|
Implantable devices for heart valve repair and replacement
|
Locked | Locked | 2009 | Locked | |
|
Catheter-based heart valve implantation and aortic therapy systems are developed.
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Venus MedTech
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Venus MedTech
Detailed financials for Venus MedTech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Venus Medtech Comparisons
Peer comparison for Venus MedTech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Venus MedTech
Venus MedTech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Shockwave Medical, Cardiac Dimensions, Pi-Cardia, Symetis and Peijia Medical Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cardiovascular balloon dilation catheters with lithotripsy electrodes are developed.
|
|
| Locked | Locked | Locked |
Invasive cardiac implants for heart failure treatment are developed.
|
|
| Locked | Locked | Locked |
Non-implant devices for cardiac valve repair are developed and manufactured.
|
|
| Locked | Locked | Locked |
Minimally invasive heart valve replacement devices are developed and marketed.
|
|
| Locked | Locked | Locked |
Medical devices for cardiac and cerebrovascular treatments are developed.
|
Detailed competitors of Venus MedTech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Venus Medtech
Complete news archive for Venus MedTech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Venus MedTech
Venus MedTech was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Venus MedTech is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.
Eric Zi is the current CEO of Venus MedTech. They have also founded this company.
Venus MedTech is a funded company, having raised a total of $37M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Venus MedTech is 691.
Annual revenue of Venus MedTech is $65.73M as on Dec 31, 2024.
Venus MedTech is a developer of medical products used during cardiovascular surgeries. Venus Medtech develops and manufactures an advanced interventional artificial cardiac valve system. Additionally, its products include artificial aorta, pulmonary artery, conveying system, compression loading system, etc. Has applied for multiple patents. As of July 2016, Its transcatheter aortic valves have completed clinical trials and follow-up and are pending China Food and Drug Administration (CFDA) clearance, and its transcatheter pulmonic valves are completing it clinical trials. Both of the valves are expected to be the first transcatheter valves approved in China. They are also developing the next-generation heart valves with pre-crimping technology. In 2016, -Transcatheter Technologies a medical device company that has developed a full range of transcatheter valve implantation systems for catheter-based heart valve therapy, announced that it had sold its technology portfolio to Venus Medtech.
Venus MedTech's top competitors include Shockwave Medical, Cardiac Dimensions and JenaValve Technology.
Yes, Venus MedTech is publicly traded on HKEX under the ticker symbol 2500.
Venus MedTech has made 5 acquisitions, including InterValve, Keystone Heart, and Transcatheter Technologies.
Venus MedTech has 4 investors. Key investors include Qiming Venture Partners, DCP, Goldman Sachs Investment Partners, and DNV Capital.
The ticker symbol of Venus MedTech is 2500 on HKEX.